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Rakesh M. Suri, MD, DPHIL, Ahmad Edris, MD, Faisal Hasan, MDSEE PAGE 1735I n patients requiring heart valve replacement,biologic valve substitutes have been implantedwith increasing frequency over the past decade.
According to the Society of Thoracic Surgeons (STS)
database, bioprosthetic valve implants in the aortic
position have increased from 43.6% in 1997 to 78.4%
in 2006 (1). A similar trend has been seen for mitral
valve replacement (2). The trend has largely been
driven by an effort to free patients from reliance on
valve-related anticoagulation despite recent evidence
warning of a possible negative prognostic impact in
individuals younger than 60 years of age (3). Further,
notwithstanding improvements in hemodynamics
and durability of third-generation devices, biopro-
sthetic valves are associated with an increased risk
of structural valve deterioration, particularly in
patients younger than 65 years of age (4–7).
When bioprosthetic valves fail, reintervention has
historically required repeat sternotomy; however, a
signiﬁcant proportion of these patients are at high risk
of surgical reintervention. Transcatheter valve-in-
valve (VIV) implantation has emerged as a less inva-
sive alternative to surgical valve replacement, offered
within the conﬁnes of clinical trials in select high-risk
patients. Transcatheter VIV replacement permits
treatment of stenotic or regurgitant biological surgical
valves by anchoring an expandable device within the
dysfunctional valve. Initial global experience can be
summarized as follows: 1) patients were typically
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in-hospital mortality; 3) cases of elevated post-
procedural gradients and compromised valve perfor-
mance were reported despite symptomatic improve-
ment; 4) cases of device dislodgment or embolization
have been identiﬁed, especially after transcatheter
mitral VIV implantation; and 5) life-threatening po-
tential complications such as device malposition and
coronary ostial coronary obstruction may require im-
mediate surgical rescue (8–12). Despite the availability
of these paradigm-changing early experiences with
transcatheter VIV implantation suggesting safety and
early efﬁcacy for high-risk patients with failing bio-
prosthetic valves, longer term follow-up data to sup-
port wider adoption were previously unavailable.In the longest available follow-up to date, Ye et al.
(13) present in this issue of JACC: Cardiovascular
Interventions their 8-year single-center experience in
73 elderly high-risk surgical patients with symptom-
atic severe aortic and mitral bioprosthetic valve
dysfunction undergoing transcatheter VIV implanta-
tion. The median STS risk score was 9.6. Most pa-
tients received balloon expandable SAPIEN or
SAPIEN XT valves (Edwards Lifesciences, Inc., Irvine,
California) via a transfemoral approach. Mitral VIV
implantation was only performed using transapical
access. The median follow-up was 2.52 years, and
the longest was 8 years. Successful implantation
occurred in 98.6% of patients with embolization of a
SAPIEN valve into the left ventricle seen in 1 patient
during transapical aortic VIV implantation requiring
immediate conversion to open surgery. Overall
30-day mortality was 1.4%, with 88.9% and 40.5% of
patients surviving at 1 and 5 years, respectively.
These ﬁndings compare favorably with the 5-year
follow-up data from the PARTNER cohort A
study (14). An important independent predictor of
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1746diminished survival using multivariate analysis was
small aortic surgical valve size (19 and 21 mm) versus
those larger than 23 mm (hazard ratio: 6.186 [95% CI:
1.001 to 22.82]; p ¼ 0.013). In terms of transcatheter
valve performance, there was a signiﬁcant reduction
in surgical prosthetic valvular pressure gradients for
both aortic and mitral valves and an increase in valve
area after VIV therapy at 12-month follow-up. This
translated into signiﬁcant clinical improvement in
heart failure symptoms that was durable for the
majority of patients and for 1 patient up to 8 years.
These clinical ﬁndings identify for the ﬁrst time
the stability and laudable midterm performance
associated with transcatheter VIV therapy. There are
several key points to consider from this registry. First,
the importance of multidisciplinary heart team
assessment is paramount when deciding between
open surgical valve revision and transcatheter VIV
implantation. Both methods of treating senescent
surgical bioprostheses are valid in the modern era, and
therapeutic choices should be tailored according to
patient risk factors, anatomy, and preference. Second,
despite the very good midterm outcomes with VIV
implantation, the report reﬂects the single-center
experience of proﬁcient transcatheter aortic valve
implantation operators. Third, the transfemoral
approach may have been associated with a reduced
length of hospitalization. The operators used the
transapical access for transcatheter mitral VIV im-
plantation because they thought it provided direct and
coaxial access; however, transvenous transcatheter
mitral VIV implantation has also recently been shown
to be feasible and safe (15). Fourth, despite symp-
tomatic improvement, transcatheter valve hemody-
namic performance was concerning in patients with
aortic surgical valves 19 and 21 mm in size, which, ac-
cording to the authors, could have diminished
late survival. Comparatively, in a larger cohort of pa-
tients from interim PARTNER II NR3 VIV Registry data,
there was no difference in 1-year outcomes
with respect to surgical heart valve size (21 mm vs. >23
mm) or transcatheter valve size (23 mm vs. 26 mm).
Fifth, preoperative evaluation using computed to-
mography (CT) angiography is essential regardless of
the surgical valve used or knowledge of the
manufacturer-reported valve dimensions. Anatomic
and technical considerations identiﬁed during CT
preoperative planning may minimize the risk ofcoronary occlusion, particularly in patients with
stentless or internally stented bioprosthetic
valves (16). Sixth, thrombus identiﬁed on some
transcatheter mitral valves suggests that further study
is needed regarding anticoagulation strategy after
transcatheter mitral VIV implantation. Finally,
although balloon valvuloplasty was used selectively in
this registry in transfemoral cases with severe bio-
prosthetic stenosis without signiﬁcant complications,
it may not be uniformly required, which is important
given potential susceptibilities of severe regurgita-
tion, debris embolization, and stroke (17).
Transcatheter VIV implantation offers clinicians an
important new treatment for high-risk patients with
senescent bioprosthetic valves. Deﬁnitions of appro-
priate patient selection criteria and best practices
during technical implantation are rapidly evolving
as experience with this therapy grows. The present
series advances our understanding of the midterm
durability and clinical outcomes that can be expected
several years after treatment. The potential for
compromise of hemodynamic and survival outcomes
must be acknowledged when VIV therapy is consid-
ered in patients with small (19 and 21 mm) surgical
valves. Whether newer devices such as the SAPIEN 3
(18) or self-expanding, supra-annular transcatheter
valves such as the CoreValve (Medtronic, Minneapolis,
Minnesota) may better serve this population is unclear
and requires further study. A multidisciplinary team
of surgeons, interventionalists, and imaging experts
should carefully select candidates for transcatheter
VIV implantation. Moreover, because surgical rescue
may be required in the event of coronary occlusion,
valve embolization, or other complications, true
collaboration during technical performance of the
procedure is critical to keep all parties fully invested
in ensuring the best outcome for the patient. The
availability of transcatheter VIV implantation has
changed the paradigm of senescent biologic heart
valve therapy and should be performed at centers with
mature transcatheter heart teams to replicate the su-
perb midterm results obtained in the present series.
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